any rally. Wasn't there a guy named smarty on here that was VERY optimistic? At least Helios can take his place....
Pretty silent Biomattica....you seemed a bit more loud when you thought you knew what you were talking about. How's that short position?
Were you saying something Biomattica? Like I said...better to invest in what you know then to invest in what you dont...Hard lesson there if you were short
Doc glad to see you are still here to moderate the board between the shorts and the pumpers. I agree with you that having Bayer is a good sign but I also know how they can #$%$ up a partnership with a biggie. (Pfizer) As for insider buying I did talk to them and all they will say is that while there is pending talks with other companies they take their DEC rules very seriously. Which sounds good to us share holders and also keeps them from having to put skin in the game because no one really knows really what is going on. You just have to not buy into their "BS" and only go with what you know. My position now is very small. I took some selling opportunity and will use it to offset my other gains. I hope you and Lyle can make some money here and I wish you all the best. I will hang on to my last few shares (5K) to see where it goes. Cheers
to the next level. This is a huge win for ACUR and a good one for Bayer to use this technology for their other products. Finally these knit wits did something right. Onward to more licensing deals.
Research and development costs for Fiscal 2015 were approximately $14.8 million, an increase of approximately $10.9 million or approximately 275% from $4.0 million of such costs for the comparable period of the prior year.
General and administrative expenses for Fiscal 2015 were $2.9 million an increase of $0.8 million or approximately 40% from $2.1 million of general and administrative expenses for the comparable period of the prior year. The increase was primarily due to significant increases in regulatory and regulatory compliance costs, including, without limitation, increased fees paid to the US-FDA and the hiring of additional staff to support regulatory compliance activities, additional costs incurred in relation to compliance with the Sarbanes-Oxley Act and significant increases in legal fees, insurance and employee benefits. Please note that these higher levels of overhead costs are expected to continue.
Depreciation and amortization for Fiscal 2015 was $0.6 million, an increase of $0.1 million or approximately 23%, from $0.5 million for the comparable period of the prior year. The increase was primarily due to the expansion and upgrading of the Northvale Facility, which has required substantial investments in property, plant and equipment.
Non-cash compensation through the issuance of stock options and warrants for Fiscal 2015 was approximately $0.3 million, an increase of $0.17 million, or approximately 205% from $0.09 million for the comparable period of the prior year.
jdm you have been here long enough to know this stock makes zero sense when there is a sell off. Keep your powder for Greenrogers call. Buy on the way up not down. With that said I am stupid and have bought more but have plenty left to buy as it dips lol
Helios, really? you wish bad things like this on someone? Karma is a biatch. Take your money and move on if this is the banter you want to spew.
The company is developing a technology to overcome abuses associated with oxycodone and other opioid analgesics.
Last week IntelliPharma said regulators won't require it to conduct Phase III studies on Rexista Oxydontin if bioequivalence to Oxycontin is demonstrated. Results of three definitive Phase I trials released in March all met the bioequivalence criteria, and IntelliPharma said it believes Phase III studies won't be required.
The product could, if successful, decrease the desirability of taking more tablets than prescribed, potentially resulting in fewer accidental or intentional deaths, according to the company.
"To the best of our knowledge, no other product currently approved for sale in the U.S. or Canada has demonstrated this potential," Chief Executive Isa Odidi said in a statement Tuesday.
Separately, on Tuesday, the company said it hasn't obtained final FDA approval for 5 milligram strength of its generic Focalin extended release treatment for attention deficit disorder.
Agreed but 27% of a population of patients that have a poor prognosis is pretty good. They seem to think that out of all the patients in each group that they will have better results once they identify the ones that Custirsen is best suited for. How they plan on doing that will be interesting to hear. I say we get a .50 to .75 cent pop.
I have been invested here since below 5. I am well aware of the "genre". I will stick to what I "know" unlike you guys that are betting on the "unknown" and "what if's" . You should invest in money management.
i think you are forgetting about their licensing technology Acuform. They have a strong sales team and prescription data will warn of any headwinds. They are sitting pretty good right now but I do see your argument. I am not opposed to selling when I see trouble but right now the trouble you are talking about is far away in my opinion.